Nancyclotep - Molecular imaging platform

EN
- Français
- English

Who we are

About Us

Founded in 2007, Nancyclotep develops and offers solutions ranging from R&D to clinical studies and production, to meet the needs of transferring radiopharmaceuticals into clinical practice.

Nancyclotep is a public-private economic interest group based at the University Hospital of Nancy (France) and employs 20 people.

Clinical trials

PET exams performed

Preclinical studies

Our work benefits from the support of public partners committed to the scientific influence of Nancy and the Grand Est Region.

Discover our partners

What we do

Activities

Nancyclotep brings together the entire radiopharmaceutical chain on a single site, from research to clinical practice.

Clinical research

A clinical research team available to the nuclear medicine department.

Discover

Radiochemistry

A laboratory dedicated to research and development in radiochemistry.

Discover

Preclinical research

Supporting investigators through the various phases of a project.

Discover

Image processing

A cross-disciplinary unit dedicated to nuclear medicine, from clinical to preclinical.

Discover

Clinical studies

Trials advancing nuclear medicine

Nancyclotep supports academic and industrial sponsors throughout the entire course of a clinical study, from the inclusion of the first patients to the publication of results.

Phase II Study evaluating lutetium (¹⁷⁷Lu) vipivotide tetraxetan in patients with progressive metastatic castration-resistant prostate cancer (mCRPC) with moderate or severe renal impairment or normal renal function Read more Phase 1b/III Phase 1b/3 randomized, controlled, open-label trial comparing RYZ101 with standard treatment in patients with inoperable, advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET) expressing somatostatin receptors (SSTR+) that progressed after prior treatment with a ¹⁷⁷Lu-labeled somatostatin analogue (¹⁷⁷Lu-SSA) Read more Phase I A multicenter, open-label, non-randomized Phase 1/2 study to assess safety,tolerability, and imaging characteristics of [⁶⁸Ga]Ga-DPI-4452 and to assess safety, tolerability, and efficacy of [¹⁷⁷Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors Read more

Our team

A multidisciplinary team

Chemists, pharmacists, physicians, biologists, technicians... Nancyclotep brings together around twenty people around a shared goal: accelerating the transfer of radiopharmaceuticals into clinical practice.